ORG Partners LLC Trims Stake in Zoetis Inc. (NYSE:ZTS)

ORG Partners LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 76.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 515 shares of the company’s stock after selling 1,664 shares during the quarter. ORG Partners LLC’s holdings in Zoetis were worth $101,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in ZTS. Webster Bank N. A. lifted its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares in the last quarter. Quarry LP raised its stake in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC purchased a new position in Zoetis in the first quarter valued at $43,000. Hazlett Burt & Watson Inc. grew its stake in Zoetis by 60.7% during the 1st quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares in the last quarter. Finally, Central Valley Advisors LLC acquired a new stake in Zoetis in the 2nd quarter valued at about $49,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.1 %

NYSE:ZTS opened at $192.39 on Wednesday. The company has a market capitalization of $87.79 billion, a PE ratio of 37.07, a P/E/G ratio of 2.95 and a beta of 0.89. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock’s 50 day moving average price is $188.57 and its 200 day moving average price is $176.58. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same period last year, the firm posted $1.41 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, research analysts anticipate that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.90%. Zoetis’s payout ratio is 33.14%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus lifted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler boosted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.